131 related articles for article (PubMed ID: 25013160)
1. Does TP53 guard ALL genomes?
Moorman AV
Blood; 2014 Jul; 124(2):160-1. PubMed ID: 25013160
[TBL] [Abstract][Full Text] [Related]
2. Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival.
Salmoiraghi S; Montalvo ML; Ubiali G; Tosi M; Peruta B; Zanghi P; Oldani E; Boschini C; Kohlmann A; Bungaro S; Intermesoli T; Terruzzi E; Angelucci E; Cavattoni I; Ciceri F; Bassan R; Rambaldi A; Spinelli O
Haematologica; 2016 Jun; 101(6):e245-8. PubMed ID: 26992948
[No Abstract] [Full Text] [Related]
3. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy.
Chiaretti S; Brugnoletti F; Tavolaro S; Bonina S; Paoloni F; Marinelli M; Patten N; Bonifacio M; Kropp MG; Sica S; Guarini A; Foà R
Haematologica; 2013 May; 98(5):e59-61. PubMed ID: 23403321
[No Abstract] [Full Text] [Related]
4. Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome.
Barnea Slonim L; Gao J; Burkart M; Odetola OE; Kocherginsky M; Dinner SN; Lu X; Wehbe F; Jennings L; Altman JK; Mirza KM; Chen YH; Sukhanova M
Leukemia; 2021 Jul; 35(7):2097-2101. PubMed ID: 33087830
[No Abstract] [Full Text] [Related]
5. Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia.
Chitadze G; Stengel A; John-Klaua C; Bruckmüller J; Trautmann H; Kotrova M; Darzentas F; Kelm M; Pal K; Darzentas N; Bastian L; Kehden B; Wessels W; Ströh AS; Oberg HH; Altrock PM; Baer C; Meggendorfer M; Gökbuget N; Baldus CD; Haferlach C; Brüggemann M
Blood; 2023 Mar; 141(13):1640-1644. PubMed ID: 36450137
[No Abstract] [Full Text] [Related]
6. Therapeutic targeting of mutated p53 in acute lymphoblastic leukemia.
van Leeuwen FN
Haematologica; 2020 Jan; 105(1):10-11. PubMed ID: 31894096
[No Abstract] [Full Text] [Related]
7. TP53 alterations in relapsed childhood acute lymphoblastic leukemia.
Yu CH; Chang WT; Jou ST; Lin TK; Chang YH; Lin CY; Lin KH; Lu MY; Chen SH; Wu KH; Wang SC; Chang HH; Su YN; Hung CC; Lin DT; Chen HY; Yang YL
Cancer Sci; 2020 Jan; 111(1):229-238. PubMed ID: 31729120
[TBL] [Abstract][Full Text] [Related]
8. TP53 in adult acute lymphoblastic leukemia.
Salmoiraghi S; Rambaldi A; Spinelli O
Leuk Lymphoma; 2018 Apr; 59(4):778-789. PubMed ID: 28679301
[TBL] [Abstract][Full Text] [Related]
9. TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis.
Stengel A; Schnittger S; Weissmann S; Kuznia S; Kern W; Kohlmann A; Haferlach T; Haferlach C
Blood; 2014 Jul; 124(2):251-8. PubMed ID: 24829203
[TBL] [Abstract][Full Text] [Related]
10. High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia.
Pourhassan H; Yang D; Afkhami M; Pillai R; Ball B; Al Malki M; Salhotra A; Ali H; Artz A; Curtin P; Armenian S; Stein A; Forman SJ; Marcucci G; Pullarkat V; Nakamura R; Aldoss I
Am J Hematol; 2022 May; 97(5):E171-E173. PubMed ID: 35132678
[No Abstract] [Full Text] [Related]
11. Mast cell sarcoma transdifferentiated from clonally-related T-lymphoblastic leukemia upon acquisition of
Gao J; Fu L; Lu X; Sukhanova M; Frankfurt O; Mohtashamian A; Chadburn A; Jennings L; Aqil B; Chen Q; Chen YH
Leuk Lymphoma; 2021 Dec; 62(13):3304-3307. PubMed ID: 34261406
[No Abstract] [Full Text] [Related]
12. Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia.
Vilas-Zornoza A; Agirre X; Martín-Palanco V; Martín-Subero JI; San José-Eneriz E; Garate L; Álvarez S; Miranda E; Rodríguez-Otero P; Rifón J; Torres A; Calasanz MJ; Cruz Cigudosa J; Román-Gómez J; Prósper F
PLoS One; 2011 Feb; 6(2):e17012. PubMed ID: 21386967
[TBL] [Abstract][Full Text] [Related]
13.
Comeaux EQ; Mullighan CG
Cold Spring Harb Perspect Med; 2017 Mar; 7(3):. PubMed ID: 28003275
[TBL] [Abstract][Full Text] [Related]
14. p16: at last a tumor suppressor gene involved in childhood acute lymphoblastic leukemias!
Leblanc T
Pediatr Hematol Oncol; 1997; 14(2):iii-viii. PubMed ID: 9089734
[No Abstract] [Full Text] [Related]
15. Identification of TP53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing.
Powell BC; Jiang L; Muzny DM; Treviño LR; Dreyer ZE; Strong LC; Wheeler DA; Gibbs RA; Plon SE
Pediatr Blood Cancer; 2013 Jun; 60(6):E1-3. PubMed ID: 23255406
[TBL] [Abstract][Full Text] [Related]
16. Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Evolves from TP53-Mutated Clonal Hematopoiesis.
Saiki R; Ogawa S
Blood Cancer Discov; 2023 Mar; 4(2):102-105. PubMed ID: 36779909
[TBL] [Abstract][Full Text] [Related]
17. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.
Hof J; Krentz S; van Schewick C; Körner G; Shalapour S; Rhein P; Karawajew L; Ludwig WD; Seeger K; Henze G; von Stackelberg A; Hagemeier C; Eckert C; Kirschner-Schwabe R
J Clin Oncol; 2011 Aug; 29(23):3185-93. PubMed ID: 21747090
[TBL] [Abstract][Full Text] [Related]
18. Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%.
Mühlbacher V; Zenger M; Schnittger S; Weissmann S; Kunze F; Kohlmann A; Bellos F; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 Jun; 53(6):524-36. PubMed ID: 24619868
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia.
Demir S; Boldrin E; Sun Q; Hampp S; Tausch E; Eckert C; Ebinger M; Handgretinger R; Kronnie GT; Wiesmüller L; Stilgenbauer S; Selivanova G; Debatin KM; Meyer LH
Haematologica; 2020 Jan; 105(1):170-181. PubMed ID: 31073076
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
Kanagal-Shamanna R; Jain P; Takahashi K; Short NJ; Tang G; Issa GC; Ravandi F; Garcia-Manero G; Yin CC; Luthra R; Patel KP; Khoury JD; Montalban-Bravo G; Sasaki K; Kadia TM; Borthakur G; Konopleva M; Jain N; Garris R; Pierce S; Wierda W; Estrov Z; Cortes J; O'Brien S; Kantarjian HM; Jabbour E
Cancer; 2017 Oct; 123(19):3717-3724. PubMed ID: 28608976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
